Summary - TVTX - NASDAQ - Weiss Ratings

E

Travere Therapeutics, Inc. TVTX

$29.73 $1.485.24% NASDAQ

Recommendation

Prev Close

Volume

Avg Vol (90D)

Market Cap

Dividend & Yield

--

52-Week Range

$12.91 - $42.13

P/E (TTM)

--

EPS (TTM)

My Lists My Alerts

Biotechnology Health Care Pharmaceutical

Access our Premium Ratings

Get Access

Rating

Reward

Risk

Rating Factors

Growth Index

Efficiency Index

Solvency Index

Total Return Index

Volatility Index

Dividend Index

Headlines

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX) and Boston Scientific (BSX)

1/22/2026 - TipRanks Financial Blog

Travere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 10,000 Shares

1/22/2026 - MarketBeat

Emerald Advisers LLC Increases Holdings in Travere Therapeutics, Inc. $TVTX

1/22/2026 - MarketBeat

Will FDA's Extended FILSPARI FSGS Review Timeline Change Travere Therapeutics' (TVTX) Narrative

1/22/2026 - Simply Wall St

Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $273,400.00 in Stock

1/21/2026 - MarketBeat

Travere Therapeutics put volume heavy and directionally bearish

1/21/2026 - TipRanks Financial Blog

Travere Therapeutics put volume heavy and directionally bearish

1/21/2026 - The Fly

14 Best Mid-Cap Growth Stocks to Buy Right Now

1/21/2026 - Insider Monkey

CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?

1/20/2026 - Zacks Investment Research

Stephens Investment Management Group LLC Purchases Shares of 1,599,668 Travere Therapeutics, Inc. $TVTX

1/17/2026 - MarketBeat

Mirum Stock Rises 7% in a Week: Here's What You Should Know

1/16/2026 - Zacks Investment Research

First Week of September 18th Options Trading For Travere Therapeutics (TVTX)

1/16/2026 - Nasdaq News: Stocks

First Week of September 18th Options Trading For Travere Therapeutics (TVTX)

1/16/2026 - Stock Options Channel

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

1/16/2026 - Business Wire

Equities Analysts Issue Forecasts for TVTX FY2030 Earnings

1/15/2026 - MarketBeat

Travere Therapeutics 2026 Outlook: Filspari Momentum, FSGS FDA Delay, And Market Potential

1/15/2026 - SeekingAlpha

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

1/14/2026 - GuruFocus

INVESTOR ALERT: Investigation of Travere Therapeutics, Inc. (TVTX) by Holzer & Holzer, LLC

1/14/2026 - Globe Newswire

Notable ETF Inflow Detected - XBI, FOLD, HALO, TVTX

1/14/2026 - ETF Channel

TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA

1/14/2026 - Zacks Investment Research

Travere Therapeutics (TVTX, $29.11) RSI Indicator left the oversold zone on January 13, 2026

1/14/2026 - Tickeron - Stocks

Wedbush Remains a Buy on Travere Therapeutics (TVTX)

1/14/2026 - TipRanks Financial Blog

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $38.71 Consensus Price Target from Brokerages

1/14/2026 - Ticker Report

Travere Therapeutics price target lowered by $4 at BofA, here's why

1/14/2026 - The Fly

fda delays decision traveres filspari 2b kidney disease indication

1/14/2026 - FiercePharma

Income Statement

Total Revenue (TTM)

EBITDA (TTM)

EBIT (TTM)

Net Income (TTM)

Balance Sheet

Total Assets (Q)

Total Debt (Q)

Total Liabilities (Q)

Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)

Cash from Investing (TTM)

Cash from Financing (TTM)

Net Change in Cash (TTM)

Filings

Filing Date

Thursday, October 30, 2025

Period Date

Tuesday, September 30, 2025

Next Filing

Week of Feb 16 and 20 (est)

Price History

Loading...

Beta

7-Day Total Return

30-Day Total Return

60-Day Total Return

90-Day Total Return

Year to Date Total Return

1-Year Total Return

2-Year Total Return

3-Year Total Return

5-Year Total Return

52-week Low

Apr 09, 2025 - $12.91

52-week High

Dec 24, 2025 - $42.13

Valuation

Market Cap

$2.53B - Mid Cap

Enterprise Value

Price/Sales (TTM)

Price/Book (Q)

Dividends and Shares

Shares Outstanding

Dividend Per Share (Most Recent)

--

Dividend Per Share (TTM)

--

Corporate Info

Website

www.travere.com

Phone Number

888 969 7879

Address

3611 Valley Centre Drive
San Diego, CA 92130

Country

Year Founded

Business Description

Sector

Industry

Pharmaceuticals, Biotechnology and Life Sciences

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s... more